First Brands Group debt targeted by Apollo Global Management - report
Director Mark Coleman of Axsome Therapeutics (NASDAQ:AXSM) recently purchased a total of 1,575 shares of common stock in three separate transactions. The purchases, all executed on September 8, 2025, were made at prices ranging from $127.20 to $127.40, resulting in a total investment of $200,466. The timing appears strategic, as the $6.27 billion biopharmaceutical company has demonstrated strong momentum with a 48.54% gain year-to-date and maintains impressive gross profit margins of 91.48%.
Specifically, Coleman acquired 800 shares at $127.20, 287 shares at $127.30, and 488 shares at $127.40. Following these transactions, Coleman directly owns 48,212 shares of Axsome Therapeutics. According to InvestingPro analysis, analysts have set price targets ranging from $144 to $200, suggesting potential upside from current levels. Get access to 8 more exclusive ProTips and comprehensive analysis with InvestingPro.
Coleman also indirectly owns 403,856 shares held by an entity where he has voting and dispositive power.
In other recent news, Axsome Therapeutics has been the subject of several analyst evaluations and regulatory developments. Wells Fargo initiated coverage on the company with an Overweight rating and set a price target of $163.00. This comes as Axsome plans to submit a supplemental New Drug Application for its AXS-05 treatment for Alzheimer’s Disease Agitation by the third quarter of 2025. Meanwhile, H.C. Wainwright reiterated its Buy rating with a $180.00 price target following a generic challenge to Axsome’s Symbravo medication.
Additionally, Mizuho maintained its Outperform rating and a $200.00 price target, also amid the generic challenge to Symbravo, which was disclosed in an 8-K filing. Axsome received a Paragraph IV Certification Notice Letter from Apotex Inc., which has submitted an Abbreviated New Drug Application to manufacture a generic version of Symbravo. Axsome has indicated plans to respond to this notice. RBC Capital reiterated an Outperform rating with a $189.00 price target, emphasizing the FDA’s flexibility in approving neuro-psychiatric drugs like AXS-05.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.